CNP-106 Clinical Trial Myasthenia Gravis
PURPOSE
The main aim of this study is to see how safe and tolerable CNP-106, an investigational drug, is for people with Myasthenia Gravis. The study will help determine if CNP-106 can help improve your MG symptoms by reprogramming your immune system. All participants will receive CNP-106 or Placebo intravenously on Day 1, Day 8, and for some Day 90.
Key Inclusion Requirements
- Men and Women ages 18-75 years old
- Positive test for antibodies to acetylcholine receptors
- Myasthenia Gravis Foundation of America Clinical Classification Class III-IV
Key Exclusion Requirements
- Myasthenia Gravis Foundation of America Clinical Classification Class I or Class V
- If you have received a COVID-19 vaccine within 14 days of screening or are planning to receive any vaccination during your time on the study
Active Clinical Sites
Infusion for Health
Brea, CA
Contact: Danielle Mendoza
Phone: (1) 626-536-8974
University of South Florida
Tampa, FL
Contact: Alexis Flores
Phone: (1) 813-974-9752
Nerve and Muscle Center of Texas
Houston, TX
Contact: Amy Megerle
Phone: (1) 713-795-0033 ext. 14
Virginia Commonwealth University
Richmond, VA
Contact: Taylor Parkinson
Phone: (1) 804-482-1833
Clinicaltrials.gov
Clinical Trial Identifier
A Clinical Trial Identifier is a unique number assigned to a clinical trial by clinical trial registries around the world.